{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:28:45Z","timestamp":1786991325289,"version":"build-2736575974"},"reference-count":98,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["K08AR084045"],"award-info":[{"award-number":["K08AR084045"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jaci-inpractice.org","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jaip.2024.05.035","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T02:24:10Z","timestamp":1716949450000},"page":"2260-2267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Beyond Avoidance: Advanced Therapies for Contact Dermatitis"],"prefix":"10.1016","volume":"12","author":[{"given":"Lu","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ungar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1481-9589","authenticated-orcid":false,"given":"Theodora K.","family":"Karagounis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2024.05.035_bib1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/cod.13119","article-title":"Prevalence of contact allergy in the general population: a systematic review and meta-analysis","volume":"80","author":"Alinaghi","year":"2019","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jaip.2024.05.035_bib2","series-title":"Dermatology","first-page":"262","article-title":"Irritant contact dermatitis","author":"Cohen","year":"2018"},{"key":"10.1016\/j.jaip.2024.05.035_bib3","series-title":"Dermatology","first-page":"81","article-title":"Immunology","author":"Schwartz","year":"2018"},{"key":"10.1016\/j.jaip.2024.05.035_bib4","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1038\/jid.2013.239","article-title":"Mechanisms of contact sensitization offer insights into the role of barrier defects vs. intrinsic immune abnormalities as drivers of atopic dermatitis","volume":"133","author":"Dhingra","year":"2013","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2024.05.035_bib5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-021-00271-4","article-title":"Contact dermatitis","volume":"7","author":"Scheinman","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jaip.2024.05.035_bib6","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1346-8138.2010.00845.x","article-title":"Hand dermatitis\/eczema: current management strategy","volume":"37","author":"Sehgal","year":"2010","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaip.2024.05.035_bib7","series-title":"StatPearls","article-title":"Topical corticosteroids","author":"Gabros","year":"2024"},{"key":"10.1016\/j.jaip.2024.05.035_bib8","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1111\/bcp.13596","article-title":"Anti-inflammatory potency testing of topical corticosteroids and calcineurin inhibitors in human volunteers sensitized to diphenylcyclopropenone","volume":"84","author":"Mose","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaip.2024.05.035_bib9","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1684\/ejd.2011.1615","article-title":"Tacrolimus 0.1% vs mometasone furoate topical treatment in allergic contact hand eczema: a prospective randomized clinical study","volume":"22","author":"Katsarou","year":"2012","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaip.2024.05.035_bib10","series-title":"StatPearls","article-title":"Calcineurin inhibitors","author":"Safarini","year":"2024"},{"key":"10.1016\/j.jaip.2024.05.035_bib11","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1067\/S0190-9622(03)01826-7","article-title":"Tacrolimus ointment 0.1% in the treatment of nickel-induced allergic contact dermatitis","volume":"49","author":"Saripalli","year":"2003","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2024.05.035_bib12","first-page":"349","article-title":"SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge","volume":"42","author":"Queille-Roussel","year":"2000","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jaip.2024.05.035_bib13","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1056\/NEJM199709183371203","article-title":"A\u00a0short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group","volume":"337","author":"Ruzicka","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2024.05.035_bib14","doi-asserted-by":"crossref","first-page":"100","DOI":"10.31138\/mjr.31.1.100","article-title":"Basic mechanisms of JAK inhibition","volume":"31","author":"Lin","year":"2020","journal-title":"Mediterr J Rheumatol"},{"key":"10.1016\/j.jaip.2024.05.035_bib15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/cod.14303","article-title":"Treatment with delgocitinib cream improves itch, pain and other signs and symptoms of chronic hand eczema: results from the Hand Eczema Symptom Diary in a phase IIb randomized clinical trial","volume":"89","author":"Bauer","year":"2023","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jaip.2024.05.035_bib16","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/bjd.18469","article-title":"Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study","volume":"182","author":"Worm","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2024.05.035_bib17","doi-asserted-by":"crossref","first-page":"AB138","DOI":"10.1016\/j.jaad.2019.06.519","article-title":"Topical delgocitinib is an efficacious and well tolerated treatment for patients with chronic hand eczema","volume":"81","author":"Worm","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2024.05.035_bib18","series-title":"Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema: results of the Phase 3 Delta 2 trial","author":"Schliemann","year":"2023"},{"key":"10.1016\/j.jaip.2024.05.035_bib19","series-title":"Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema: results of the Phase 3 Delta 1 trial [abstract]","author":"Bissonnette","year":"2023"},{"key":"10.1016\/j.jaip.2024.05.035_bib21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s40257-022-00748-2","article-title":"Ruxolitinib cream 1.5%: a review in mild to moderate atopic dermatitis","volume":"24","author":"Hoy","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaip.2024.05.035_bib22","series-title":"StatPearls","article-title":"Corticosteroid adverse effects","author":"Yasir","year":"2024"},{"key":"10.1016\/j.jaip.2024.05.035_bib23","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/cod.13697","article-title":"Rapid response to ciclosporin in patients with Parthenium dermatitis: a preliminary study","volume":"84","author":"Verma","year":"2021","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jaip.2024.05.035_bib24","first-page":"543","article-title":"Exacerbation of allergic contact dermatitis during immunosuppression with cyclosporine A","volume":"145","author":"Prignano","year":"2010","journal-title":"G\u00a0Ital Dermatol Venereol"},{"key":"10.1016\/j.jaip.2024.05.035_bib25","series-title":"StatPearls","article-title":"Cyclosporine","author":"Tapia","year":"2024"},{"key":"10.1016\/j.jaip.2024.05.035_bib26","series-title":"StatPearls","article-title":"Azathioprine","author":"Mohammadi","year":"2023"},{"key":"10.1016\/j.jaip.2024.05.035_bib27","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/cod.14406","article-title":"Systemic treatments in Parthenium dermatitis: a systematic review and meta-analysis","volume":"89","author":"Akham","year":"2023","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jaip.2024.05.035_bib28","first-page":"535","article-title":"Methotrexate: practical use in dermatology","volume":"151","author":"Diani","year":"2016","journal-title":"G\u00a0Ital Dermatol Venereol"},{"key":"10.1016\/j.jaip.2024.05.035_bib29","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/cod.12925","article-title":"Methotrexate use in allergic contact dermatitis: a retrospective study","volume":"78","author":"Patel","year":"2018","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jaip.2024.05.035_bib30","first-page":"341","article-title":"A\u00a0phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis","volume":"11","author":"Volf","year":"2012","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.jaip.2024.05.035_bib31","first-page":"31","article-title":"Tumour necrosis factor-alpha is required for accumulation of dendritic cells in draining lymph nodes and for optimal contact sensitization","volume":"84","author":"Cumberbatch","year":"1995","journal-title":"Immunology"},{"key":"10.1016\/j.jaip.2024.05.035_bib32","first-page":"257","article-title":"Dermal tumour necrosis factor-alpha induces dendritic cell migration to draining lymph nodes, and possibly provides one stimulus for Langerhans\u2019 cell migration","volume":"75","author":"Cumberbatch","year":"1992","journal-title":"Immunology"},{"key":"10.1016\/j.jaip.2024.05.035_bib33","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/205873920601900125","article-title":"Infliximab in recalcitrant severe atopic eczema associated with contact allergy","volume":"19","author":"Cassano","year":"2006","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.jaip.2024.05.035_bib34","series-title":"StatPearls","article-title":"Tumor necrosis factor inhibitors","author":"Gerriets","year":"2024"},{"key":"10.1016\/j.jaip.2024.05.035_bib35","doi-asserted-by":"crossref","first-page":"520","DOI":"10.4103\/0019-5154.164426","article-title":"Alitretinoin in dermatology-an update","volume":"60","author":"Bubna","year":"2015","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.jaip.2024.05.035_bib36","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14911","article-title":"DECISA Project (DErmatology Clinics in Italy: Survey on Alitretinoin): a real-life retrospective cohort multicenter study on 438 subjects with chronic hand eczema","volume":"34","author":"Ferrucci","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaip.2024.05.035_bib37","doi-asserted-by":"crossref","first-page":"AB135","DOI":"10.1016\/j.jaad.2019.06.508","article-title":"The treatment efficacy of oral alitretinoin in Korean patients with chronic hand eczema: a retrospective study","volume":"81","author":"Ko","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2024.05.035_bib38","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/cod.14204","article-title":"Occupational airborne allergic contact dermatitis to invasive Compositae species treated with abrocitinib: a case report","volume":"87","author":"Baltazar","year":"2022","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jaip.2024.05.035_bib39","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/cod.14278","article-title":"Sequential patch testing in a patient treated with dupilumab then with upadacitinib: differences in patch test results as well as in disease control","volume":"88","author":"Mainville","year":"2023","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jaip.2024.05.035_bib40","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1080\/09546634.2022.2082355","article-title":"Tofacitinib in the treatment of refractory eczemas - a case series","volume":"33","author":"Duraisamy","year":"2022","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.jaip.2024.05.035_bib41","series-title":"StatPearls","article-title":"Tofacitinib","author":"Padda","year":"2024"},{"key":"10.1016\/j.jaip.2024.05.035_bib42","series-title":"StatPearl","article-title":"Upadacitinib","author":"Padda","year":"2024"},{"key":"10.1016\/j.jaip.2024.05.035_bib43","series-title":"StatPearls","article-title":"Dupilumab","author":"Gade","year":"2024"},{"key":"10.1016\/j.jaip.2024.05.035_bib44","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/DER.0000000000000414","article-title":"Dupilumab as a treatment for allergic contact dermatitis","volume":"29","author":"Chipalkatti","year":"2018","journal-title":"Dermatitis"},{"key":"10.1016\/j.jaip.2024.05.035_bib45","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/cod.13545","article-title":"Dupilumab treatment in two patients with severe allergic contact dermatitis caused by sesquiterpene lactones","volume":"83","author":"Ruge","year":"2020","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jaip.2024.05.035_bib46","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1111\/jocd.15112","article-title":"Successfully treatment with dupilumab for systemic contact dermatitis following hair dye in a patient with dermatomyositis","volume":"21","author":"Jin","year":"2022","journal-title":"J\u00a0Cosmet Dermatol"},{"key":"10.1016\/j.jaip.2024.05.035_bib47","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12701","article-title":"A\u00a0case series of dupilumab-treated allergic contact dermatitis patients","volume":"31","author":"Goldminz","year":"2018","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaip.2024.05.035_bib48","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1159\/000524380","article-title":"Occupational chronic contact dermatitis successfully treated with dupilumab: a case series","volume":"238","author":"Slodownik","year":"2022","journal-title":"Dermatology"},{"key":"10.1016\/j.jaip.2024.05.035_bib49","first-page":"1340","article-title":"Chromate-induced allergic contact dermatitis treated with dupilumab","volume":"20","author":"Wilson","year":"2021","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.jaip.2024.05.035_bib50","doi-asserted-by":"crossref","first-page":"e640","DOI":"10.1111\/jdv.18099","article-title":"Dupilumab for the treatment of refractory allergic contact dermatitis from rubber\/latex concomitant with atopic dermatitis","volume":"36","author":"Koh","year":"2022","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2024.05.035_bib51","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1111\/ajd.13740","article-title":"Treatment of generalised isobornyl acrylate contact allergy from diabetes pump with Dupilumab","volume":"63","author":"Arasu","year":"2022","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaip.2024.05.035_bib52","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/09546634.2019.1689227","article-title":"Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review","volume":"32","author":"Hendricks","year":"2021","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.jaip.2024.05.035_bib54","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/DAD.0000000000001275","article-title":"Cutaneous elastic tissue anomalies","volume":"41","author":"Andr\u00e9s-Ramos","year":"2019","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.jaip.2024.05.035_bib55","first-page":"287","article-title":"Occupational wheat contact dermatitis and treatment with omalizumab","volume":"23","author":"Mur Gimeno","year":"2013","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2024.05.035_bib56","series-title":"StatPearls","article-title":"Omalizumab","author":"Kumar","year":"2024"},{"key":"10.1016\/j.jaip.2024.05.035_bib57","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/cod.12988","article-title":"The effect of treatment with anti-interleukin-17 in patients with allergic contact dermatitis","volume":"78","author":"Todberg","year":"2018","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jaip.2024.05.035_bib58","series-title":"StatPearls","article-title":"Secukinumab","author":"Aboobacker","year":"2024"},{"key":"10.1016\/j.jaip.2024.05.035_bib59","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1146\/annurev.immunol.18.1.309","article-title":"Glucocorticoids in T cell development and function","volume":"18","author":"Ashwell","year":"2000","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaip.2024.05.035_bib60","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nri.2017.1","article-title":"Immune regulation by glucocorticoids","volume":"17","author":"Cain","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaip.2024.05.035_bib61","doi-asserted-by":"crossref","first-page":"416","DOI":"10.4103\/2229-5178.142483","article-title":"Side-effects of topical steroids: a long overdue revisit","volume":"5","author":"Coondoo","year":"2014","journal-title":"Indian Dermatol Online J"},{"key":"10.1016\/j.jaip.2024.05.035_bib62","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1111\/ijd.12641","article-title":"Tacrolimus 0.1% ointment in the treatment of allergic contact dermatitis: a new approach","volume":"53","author":"Han","year":"2014","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaip.2024.05.035_bib63","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1081-1206(10)61535-9","article-title":"Topical pimecrolimus in the treatment of human allergic contact dermatitis","volume":"91","author":"Amrol","year":"2003","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2024.05.035_bib64","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2310\/6620.2007.06031","article-title":"A\u00a0double-blind randomized placebo-controlled pilot study comparing topical immunomodulating agents and corticosteroids for treatment of experimentally induced nickel contact dermatitis","volume":"18","author":"Bhardwaj","year":"2007","journal-title":"Dermatitis"},{"key":"10.1016\/j.jaip.2024.05.035_bib65","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4103\/0378-6323.16244","article-title":"Hand eczema -- clinical patterns and role of patch testing","volume":"71","author":"Kishore","year":"2005","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaip.2024.05.035_bib66","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1600-0536.2011.01943.x","article-title":"Patch testing in children with hand eczema. A 5-year multicentre study in Spain","volume":"65","author":"Toledo","year":"2011","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jaip.2024.05.035_bib67","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jaad.2020.11.054","article-title":"Hand dermatitis in adults referred for patch testing: analysis of North American Contact Dermatitis Group Data, 2000 to 2016","volume":"84","author":"Silverberg","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2024.05.035_bib68","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1684\/ejd.2022.4234","article-title":"Chronic hand eczema: clinical characterization, aetiology, concomitant foot eczema and polysensitization","volume":"32","author":"Lopez-Castillo","year":"2022","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaip.2024.05.035_bib69","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jaad.2017.02.049","article-title":"Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib","volume":"76","author":"Rothstein","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2024.05.035_bib71","series-title":"StatPearls","article-title":"Phosphodiesterase inhibitors","author":"Padda","year":"2024"},{"key":"10.1016\/j.jaip.2024.05.035_bib72","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1211\/0022357021585","article-title":"AWD 12-281, a highly selective phosphodiesterase 4 inhibitor, is effective in the prevention and treatment of inflammatory reactions in a model of allergic dermatitis","volume":"55","author":"B\u00e4umer","year":"2003","journal-title":"J\u00a0Pharm Pharmacol"},{"key":"10.1016\/j.jaip.2024.05.035_bib73","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0014-2999(02)01810-1","article-title":"Effects of the phosphodiesterase 4 inhibitors SB 207499 and AWD 12-281 on the inflammatory reaction in a model of allergic dermatitis","volume":"446","author":"B\u00e4umer","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jaip.2024.05.035_bib74","series-title":"Meyler\u2019s side effects of drugs","first-page":"800","article-title":"Cytotoxic and immunosuppressant drugs","author":"Aronson","year":"2016"},{"key":"10.1016\/j.jaip.2024.05.035_bib75","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/bjd\/ljad156","article-title":"Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study","volume":"189","author":"Voorberg","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2024.05.035_bib76","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/cod.12691","article-title":"Azathioprine treatment and drug survival in patients with chronic hand eczema - results from daily practice","volume":"76","author":"Oosterhaven","year":"2017","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jaip.2024.05.035_bib77","first-page":"249","article-title":"Diagnosis and management of contact dermatitis","volume":"82","author":"Usatine","year":"2010","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.jaip.2024.05.035_bib78","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1600-0536.2007.01209.x","article-title":"Ciclosporin ophthalmic emulsion - a novel therapy for benzyl alcohol-associated eyelid dermatitis","volume":"58","author":"Jacob","year":"2008","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jaip.2024.05.035_bib103","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/DER.0000000000000435","article-title":"Systemic treatments for allergic contact dermatitis","volume":"30","author":"Sung","year":"2019","journal-title":"Dermatitis"},{"key":"10.1016\/j.jaip.2024.05.035_bib79","doi-asserted-by":"crossref","first-page":"364","DOI":"10.5021\/ad.2016.28.3.364","article-title":"Efficacy and safety of alitretinoin for chronic hand eczema in Korean patients","volume":"28","author":"Kwon","year":"2016","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.jaip.2024.05.035_bib80","doi-asserted-by":"crossref","first-page":"595","DOI":"10.5021\/ad.2019.31.6.595","article-title":"Efficacy and safety of alitretinoin therapy in Korean elderly patients with chronic hand eczema: a retrospective single center study","volume":"31","author":"Jo","year":"2019","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.jaip.2024.05.035_bib81","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.2165\/11202200-000000000-00000","article-title":"Alitretinoin: in severe chronic hand eczema","volume":"69","author":"Garnock-Jones","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.jaip.2024.05.035_bib82","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/j.1365-2133.2008.08487.x","article-title":"Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial","volume":"158","author":"Ruzicka","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2024.05.035_bib83","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/1744666X.2022.2060822","article-title":"The suitability of treating atopic dermatitis with Janus kinase inhibitors","volume":"18","author":"Narla","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaip.2024.05.035_bib84","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1080\/1744666X.2018.1512404","article-title":"Tofacitinib for the treatment of psoriasis and psoriatic arthritis","volume":"14","author":"Berekmeri","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaip.2024.05.035_bib85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-018-8685-0","article-title":"The unique molecular signatures of contact dermatitis and implications for treatment","volume":"56","author":"Leonard","year":"2019","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaip.2024.05.035_bib86","series-title":"Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study [abstract]","author":"Loman","year":"2023"},{"key":"10.1016\/j.jaip.2024.05.035_bib87","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/DER.0000000000000357","article-title":"Patch testing in a patient on dupilumab","volume":"29","author":"Hoot","year":"2018","journal-title":"Dermatitis"},{"key":"10.1016\/j.jaip.2024.05.035_bib88","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/DER.0000000000000346","article-title":"Positive patch test reaction in a patient taking dupilumab","volume":"29","author":"Puza","year":"2018","journal-title":"Dermatitis"},{"key":"10.1016\/j.jaip.2024.05.035_bib89","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jaad.2019.03.020","article-title":"Variable impact of dupilumab on patch testing results and allergic contact dermatitis in adults with atopic dermatitis","volume":"81","author":"Stout","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2024.05.035_bib90","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaad.2019.09.028","article-title":"The impact of dupilumab on patch testing and the prevalence of comorbid allergic contact dermatitis in recalcitrant atopic dermatitis: a retrospective chart review","volume":"82","author":"Raffi","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2024.05.035_bib91","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.1016\/j.jaad.2020.05.036","article-title":"Dupilumab for allergic contact dermatitis and implications for patch testing: Irreconcilable differences","volume":"83","author":"Shah","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2024.05.035_bib92","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0190-9622(03)70103-0","article-title":"Atopic dermatitis-like eruption precipitated by infliximab","volume":"49","author":"Wright","year":"2003","journal-title":"J\u00a0Am Acad Dermato"},{"key":"10.1016\/j.jaip.2024.05.035_bib93","first-page":"315","article-title":"Counter-regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy","volume":"3","author":"Chan","year":"2004","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.jaip.2024.05.035_bib94","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1248\/bpb.b19-00689","article-title":"Metformin suppresses LPS-induced inflammatory responses in macrophage and ameliorates allergic contact dermatitis in mice via autophagy","volume":"43","author":"Wang","year":"2020","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.jaip.2024.05.035_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110003","article-title":"Rosmarinic acid ameliorates skin inflammation and pruritus in allergic contact dermatitis by inhibiting mast cell-mediated MRGPRX2\/PLC\u03b31 signaling pathway","volume":"117","author":"Ding","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jaip.2024.05.035_bib96","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/all.13067","article-title":"Electrophilic nitro-fatty acids suppress allergic contact dermatitis in mice","volume":"72","author":"Mathers","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2024.05.035_bib97","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1046\/j.0022-202x.2001.01626.x","article-title":"Topical peroxisome proliferator activated receptor-alpha activators reduce inflammation in irritant and allergic contact dermatitis models","volume":"118","author":"Sheu","year":"2002","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2024.05.035_bib98","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/jid.2008.454","article-title":"Topical application of sphingosine-1-phosphate and FTY720 attenuate allergic contact dermatitis reaction through inhibition of dendritic cell migration","volume":"129","author":"Reines","year":"2009","journal-title":"J\u00a0Investig Dermatol"},{"key":"10.1016\/j.jaip.2024.05.035_bib99","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1046\/j.1365-2133.2002.04664.x","article-title":"Free radicals in antigen formation: reduction of contact allergic response to hydroperoxides by epidermal treatment with antioxidants","volume":"146","author":"G\u00e4fvert","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2024.05.035_bib100","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3920\/BM2020.0134","article-title":"Preventive oral supplementation with Bifidobacterium longum 5(1A) alleviates oxazolone-induced allergic contact dermatitis-like skin inflammation in mice","volume":"12","author":"Ribeiro","year":"2021","journal-title":"Benef Microbes"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219824005506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219824005506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T04:28:37Z","timestamp":1730521717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219824005506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":98,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2213219824005506"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2024.05.035","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond Avoidance: Advanced Therapies for Contact Dermatitis","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2024.05.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}